Cargando…
PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429649/ http://dx.doi.org/10.1097/01.HS9.0000975272.90871.a9 |
| _version_ | 1785090766852325376 |
|---|---|
| author | Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Fotiou, Despina Migkou, Magdalini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Theodorakakou, Foteini Spiliopoulou, Vassiliki Kastritis, Efstathios Terpos, Evangelos Dimopoulos, Meletios A. Gavriatopoulou, Maria |
| author_facet | Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Fotiou, Despina Migkou, Magdalini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Theodorakakou, Foteini Spiliopoulou, Vassiliki Kastritis, Efstathios Terpos, Evangelos Dimopoulos, Meletios A. Gavriatopoulou, Maria |
| author_sort | Ntanasis-Stathopoulos, Ioannis |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429649 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104296492023-08-17 PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Fotiou, Despina Migkou, Magdalini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Theodorakakou, Foteini Spiliopoulou, Vassiliki Kastritis, Efstathios Terpos, Evangelos Dimopoulos, Meletios A. Gavriatopoulou, Maria Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429649/ http://dx.doi.org/10.1097/01.HS9.0000975272.90871.a9 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Fotiou, Despina Migkou, Magdalini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Theodorakakou, Foteini Spiliopoulou, Vassiliki Kastritis, Efstathios Terpos, Evangelos Dimopoulos, Meletios A. Gavriatopoulou, Maria PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA |
| title | PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA |
| title_full | PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA |
| title_fullStr | PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA |
| title_full_unstemmed | PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA |
| title_short | PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA |
| title_sort | pb2127: real-world effectiveness and safety of belantamab mafodotin in triple class refractory patients with multiple myeloma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429649/ http://dx.doi.org/10.1097/01.HS9.0000975272.90871.a9 |
| work_keys_str_mv | AT ntanasisstathopoulosioannis pb2127realworldeffectivenessandsafetyofbelantamabmafodotinintripleclassrefractorypatientswithmultiplemyeloma AT malandrakispanagiotis pb2127realworldeffectivenessandsafetyofbelantamabmafodotinintripleclassrefractorypatientswithmultiplemyeloma AT fotioudespina pb2127realworldeffectivenessandsafetyofbelantamabmafodotinintripleclassrefractorypatientswithmultiplemyeloma AT migkoumagdalini pb2127realworldeffectivenessandsafetyofbelantamabmafodotinintripleclassrefractorypatientswithmultiplemyeloma AT roussoumaria pb2127realworldeffectivenessandsafetyofbelantamabmafodotinintripleclassrefractorypatientswithmultiplemyeloma AT eleutherakispapaiakovouevangelos pb2127realworldeffectivenessandsafetyofbelantamabmafodotinintripleclassrefractorypatientswithmultiplemyeloma AT theodorakakoufoteini pb2127realworldeffectivenessandsafetyofbelantamabmafodotinintripleclassrefractorypatientswithmultiplemyeloma AT spiliopoulouvassiliki pb2127realworldeffectivenessandsafetyofbelantamabmafodotinintripleclassrefractorypatientswithmultiplemyeloma AT kastritisefstathios pb2127realworldeffectivenessandsafetyofbelantamabmafodotinintripleclassrefractorypatientswithmultiplemyeloma AT terposevangelos pb2127realworldeffectivenessandsafetyofbelantamabmafodotinintripleclassrefractorypatientswithmultiplemyeloma AT dimopoulosmeletiosa pb2127realworldeffectivenessandsafetyofbelantamabmafodotinintripleclassrefractorypatientswithmultiplemyeloma AT gavriatopouloumaria pb2127realworldeffectivenessandsafetyofbelantamabmafodotinintripleclassrefractorypatientswithmultiplemyeloma |